Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides

ChemMedChem. 2011 Apr 4;6(4):678-85. doi: 10.1002/cmdc.201000463. Epub 2011 Mar 2.

Abstract

The structure and the in vitro behavior of liposomes filled with the cytotoxic drug doxorubicin (Doxo) and functionalized on the external surface with a branched moiety containing four copies of the 8-13 neurotensin (NT) peptide is reported. The new functionalized liposomes, DOPC-NT₄Lys(C₁₈)₂, are obtained by co-aggregation of the DOPC phospholipid with a new synthetic amphiphilic molecule, NT₄ Lys(C₁₈)₂, which contains a lysine scaffold derivatized with a lipophilic moiety and a tetrabranched hydrophilic peptide, NT8-13, a neurotensin peptide fragment well known for its ability to mimic the neurotensin peptide in receptor binding ability. Dynamic light scattering measurements indicate a value for the hydrodynamic radius (RH) of 88.3±4.4 nm. The selective internalization and cytotoxicity of DOPC-NT₄ Lys(C₁₈)₂ liposomes containing Doxo, as compared to pure DOPC liposomes, were tested in HT29 human colon adenocarcinoma and TE671 human rhabdomyosarcoma cells, both of which express neurotensin receptors. Peptide-functionalized liposomes show a clear advantage in comparison to pure DOPC liposomes with regard to drug internalization in both HT29 and TE671 tumor cells: FACS analysis indicates an increase in fluorescence signal of the NT₄-liposomes, compared to the DOPC pure analogues, in both cell lines; cytotoxicity of DOPC-NT₄ Lys(C₁₈)₂-Doxo liposomes is increased four-fold with respect to DOPC-Doxo liposomes in both HT29 and TE671 cell lines. These effects could to be ascribed to the higher rate of internalization for DOPC-NT₄ Lys(C₁₈)₂-Doxo liposomes, due to stronger binding driven by a lower dissociation constant of the NT₄-liposomes that bind the membrane onto a specific protein, in contrast to DOPC liposomes, which approach the plasma membrane unselectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1,2-Dipalmitoylphosphatidylcholine / chemistry
  • 1,2-Dipalmitoylphosphatidylcholine / pharmacokinetics
  • 1,2-Dipalmitoylphosphatidylcholine / pharmacology
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / pathology
  • Drug Delivery Systems*
  • Humans
  • Hydrodynamics
  • Liposomes / chemistry
  • Liposomes / pharmacokinetics
  • Liposomes / pharmacology*
  • Lysine / chemistry
  • Lysine / metabolism
  • Neurotensin* / chemistry
  • Neurotensin* / pharmacokinetics
  • Peptide Fragments* / chemistry
  • Peptide Fragments* / pharmacokinetics
  • Rhabdomyosarcoma / metabolism
  • Rhabdomyosarcoma / pathology
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Liposomes
  • Peptide Fragments
  • 1,2-Dipalmitoylphosphatidylcholine
  • Neurotensin
  • neurotensin (8-13)
  • Lysine